
usd feb pm et
summari merck one world lead brand biopharmaceut compani well
produc vaccin anim health medic
price-to-earnings oper ep
subject intens competit treatment
market share similar drug gener
challeng brand drug also risk
associ drug efficaci failur clinic trial
regulatori approv hurdl potenti new
price regul risk balanc
highli valuabl franchis diabet immuno-oncolog
vaccin also balanc pharmaceut sale
risk diversif anim health
past perform indic futur perform reli upon
analysi prepar equiti analyst
feb stock trade
sale growth yoy led grow
demand lead immuno-oncolog
drug keytruda total sale
increas sale yoy
tremend success keytruda treat
multipl type cancer off-set overal
contract rest drug portfolio
saw sale decreas yoy
expect rapid sale growth ketyruda
continu slower pace due
season sale follow rapid uptak
drug treatment lung cancer first
approv octob think keytruda
continu expand new indic
come year lung second
common type cancer reproduc
growth keytruda achiev
indic difficult view
think total sale growth slow
around
fuel tremend success keytruda
adjust pre-tax incom per share
full-year follow similar growth
earn growth experienc
headwind worsen gross profit margin
adjust cog grew materi
faster revenu
think keytruda sale total
continu grow robustli keep
like lead industry-averag ep
growth though outsid keytruda
sale declin yoy competit
immuno-oncolog space intensifi
increas risk becom
increasingli depend premier drug
view also expect slow
ketyruda growth penetr smaller
keytruda sale grew
despit tremend
growth howev adjust ep grew
annual period well-below
industri averag think fairli valu
current level demonstr
turn blockbust drug success
target price ep
estim roughli line histor
forward price-to-earnings averag risk view includ
lower-than-expect market share
keytruda potenti new regul
drug price rapid growth vaccin
apr ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview merck co lead global drugmak produc wide rang prescript
drug mani therapeut class abroad foreign oper account
total sale respect
largest-sel product includ januvia/janumet sale billion billion
treatment type diabet keytruda billion billion remicad
million billion treatment rheumatoid arthriti isentress
billion billion treatment hiv/aid remicad lost patent protect europ
late januari
merck also lead maker vaccin vaccin includ proquad measl mump rubella
chicken pox gardasil human papilloma viru main caus cervic cancer
purchas schering-plough merck gain total right zetia -- cholesterol therapi
work block cholesterol absorpt intestin -- well vytorin combin pill
contain zocor zetia zetia/vytorin sale billion billion
anim health product compris anti-infect antiparasit drug relat item sale
billion billion octob merck sold consum care product
unit includ over-the-counter brand claritin allergi dr scholl foot care product
copperton suntan lotion bayer ag billion
market profil dollar valu global drug market project grow compound-annual-growth-rate compound
annual growth rate period accord forecast made iqvia key
driver emerg market whose aggreg sale countri advanc compound-annual-growth-rate
period growth develop market spur rise standard
live grow govern spend health care howev iqvia forecast soft sale europ
combin drug spend five major european market project grow compound-annual-growth-rate
spend forecast grow compound-annual-growth-rate period
impact major develop octob complet sale consum care unit
includ brand claritin afrin copperton bayer ag billion
early-novemb acquir rival drugmak schering-plough billion cash
stock billion acquisit schering-plough fund cash
billion debt billion merck stock billion
octob keytruda approv non-smal cell lung cancer nsclc first line treatment
patient express greater second line treatment patient
express keytruda approv nsclc metastat melanoma head neck cancer well
bladder cancer expect becom top sell drug within next year
financi trend sale due sever drug patent expir fallen billion
billion expens total billion sale billion
sale billion sale billion sale
pipelin june includ three program regulatori review program phase clinic
trial program phase ii clinic trial spite declin sale abl increas
adjust ep cost cut lower share count stock repurchas adjust
ep increas repres three-year compound annual
growth rate compound-annual-growth-rate
cfo execut vice-president
offic senior vice-president
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc februari technic indic
bullish
figur base fiscal year-end price
growth rate averag
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook pharmaceut sub-industri
next year posit reflect
strong novel drug approv nda activ
food drug administr fda --
posit brand drug maker
repres lion share
improv gener profit margin
competit appear moder
overal posit view somewhat temper
expect lower growth overal
expect strong pace nda continu
next year aid continu robust
growth invest led major brand drug
compani banner year nda
fda new drug approv
repres surg approv compar
mani
new drug littl competit
provid tailwind brand drug
maker strong growth spend
primari driver novel approv uptick
industri increas
estim pace anoth year
growth septemb
growth mark rapid acceler
averag annual growth
side sub-industri
outlook earn growth gener
maker posit closer neutral fda
gener approv total
mani
compet version gener enter
sever gener
price deflat becam norm profit margin
contract surprisingli number
firm announc asset divestitur exit
 gener industri
bright side think lower competit
start impact note gener
approv tick vs
first materi declin least six
year also note move
averag gener applic lead
think anoth sign
mitig competit allow
moder gener deflat
modest improv gener profit margin
year ahead
anoth boost gener maker
record year fda first-gener approv
experienc
first-gener typic enter
market materi lower price
brand-nam counterpart allow
quick market share gain accordingli
major increas first-gener provid
revenu tailwind gener maker next
mitig posit outlook
sub-industri expect slower
prescript volum growth next
year strong gain health-insur
popul driven solid employ
growth view
think gain harder come
 approach full employ
remov tailwind prescript
volum growth assum
slower growth health plan roll gener
mean slower growth prescript volum
versu rise composit
drop
year date januari pharma
slip gain
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
announc initi result checkmat phase
trial opdivo yervoy combin treat first line advanc non-smal cell
lung cancer trial met primari endpoint one-year progression-fre
surviv compar chemotherapi overal respons rate
versu chemotherapi base earli analysi data overal
surviv encourag critic data releas yet
share sharpli competitor merck report
combin trial -- keynot made keytruda plu chemotherapi -- cut
risk death compar chemotherapi regardless
express includ patient test neg base trial
result think continu maintain sizeabl market share lung
cancer market lower target price bristol-my squibb
ep estim /jeffrey loo cfa
keep target price slightli
peer ep estim set ep
ep vs ahead estim aid lower tax
rate sale rose slightli forecast keytruda sale
solid view guid sale ep
look continu robust sale keytruda recent approv
lynparza co-partn astrazeneca treat breast cancer
anticip flat sale top sell diabet drug januvia /jeffrey loo
share significantli posit phase
result keytruda combin two chemotherapi drug first
line treatment non-smal cell lung cancer trial met
endpoint overal surviv progression-fre surviv result
submit regul believ bolster chanc approv
europ solidifi lead posit indic
withdrawn eu applic oct trial
meet endpoint fda approv alreadi receiv set /jeffrey
analyst research note compani news
et cfra keep hold opinion share merck co inc
lift target ep
estim -- roughli line histor averag forward price-to-earnings lower
ep estim start ep
vs beat consensu sale rose yoy led
growth oncolog drug keytruda total revenu quarter
fda approv keytruda part combin therapi
broadli appli treat certain form lung cancer major
mileston expect new indic maintain
keytruda robust sale growth year ahead outsid keytruda sale
declin yoy howev make increasingli depend premier drug
growth full year adjust pre-tax incom increas
increas expect stellar keytruda growth continu
think share near fair valu given lacklust growth rest drug
et cfra keep hold opinion share merck co inc
rais target price
ep estim line peer-averag rais ep
estim ep vs beat consensu
although revenu disappoint sale rose yoy led
increas sale cancer drug keytruda keytruda repres
total sale show tremend success drug
overcam sale declin rest portfolio whole
yoy profit margin also come pressur mostli due
bp increas adjust cog margin think least partial
reflect difficult drug price environ year despit
keytruda rapid growth expect continu new indic
growth aggreg portfolio ex-keytruda difficult price
rais target price in-lin
peer forward ep estim ep
vs ahead estim rais ep estim
sale includ fx benefit rose driven robust
keytruda sale rose gardasil sale anim health
sale rose believ gain market share end-market
note januvia second-best sell drug continu face price
pressur result sale growth sever regulatori
file across world addit indic keytruda includ
sbla keytruda first line treatment metastat squamou non-smal
cell lung cancer regardless express file fda action
date octob sbla ketruda treat previous treat
patient advanc hepatocellular carcinoma fda action date
et cfra keep hold opinion share merck co inc
rais target slightli
peer ep estim rais ep
estim ep vs ahead view
sale fx benefit rose driven keytruda sale
year ago sequenti slightli forecast
howev januvia sale growth slightli ahead
expect solid growth oversea partial off-set price pressur
file biolog licens applic bla keytruda combin
chemotherapi base data trial treat non-smal
cell lung cancer fda grant prioriti review bla fda action
date septemb data trial cut risk death
impress view also sbla keytruda treat
recurr metastat head neck cancer fda action date
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
